The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Unlike CRISPR, which is sort of in this liminal place where biotech companies aren't sure if they should invest or not in CRISPR because it's unclear whether or not the governing bodies are going to allow gene editing, just like it was unclear 15 years ago if they were going to allow gene therapy.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.